X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accesswire.com/852453/court-of-appeals-for-the-federal-circuit-issues-ruling-in-norwich-case-that-prevents-fda-approval-of-norwichs-abbreviated-new-drug-application-until-2029
https://www.accesswire.com/850631/bausch-health-announces-patent-lawsuit-against-amneal-pharmaceuticals
https://www.fiercepharma.com/pharma/alvogens-bid-force-fda-approve-generic-bausch-healths-ibd-d-med-xifaxan-shot-down-dc-court
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214369
https://www.accesswire.com/723896/Salix-Will-Present-Rifaximin-Data-at-AASLDs-The-Liver-MeetingR-2022
https://www.accesswire.com/721607/Salix-Will-Present-XIFAXANR-Rifaximin-TRULANCER-Plecanatide-and-RELISTORR-Methylnaltrexone-Bromide-Data-at-The-American-College-of-GastroenterologyR-2022-Annual-Scientific-Meeting
https://www.prnewswire.com/news-releases/bausch-health-responds-to-norwich-pharmaceuticals-tentative-fda-approval-for-a-200-mg-rifaximin-301621015.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214370
https://endpts.com/new-jersey-judge-decides-bausch-healths-xifaxan-is-prior-art-does-not-infringe-curia-patents/
https://www.prnewswire.com/news-releases/salix-to-share-new-data-from-xifaxan-rifaximin-clinical-research-at-easls-international-liver-congress-2022-301570834.html
https://www.biospace.com/article/releases/bausch-health-s-rifaximin-receives-fda-orphan-designation-for-sickle-cell-disease/
https://www.pharmaexcipients.com/news/effect-glyceryl-palmitostearate/
https://www.prnewswire.com/news-releases/bausch-health-and-alfasigma-announce-resolution-of-xifaxan-intellectual-property-litigation-301053561.html
https://www.prnewswire.com/news-releases/salix-to-highlight-new-data-across-its-portfolio-of-products-at-digestive-disease-week-2020-virtual-meeting-301049876.html
https://www.prnewswire.com/news-releases/bausch-health-announces-favorable-topline-results-from-study-evaluating-investigative-formulation-of-rifaximin-ssd-ir-to-treat-overt-hepatic-encephalopathy-301032189.html
https://www.biospace.com/article/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market/?s=95
https://www.fiercepharma.com/pharma/bausch-even-after-shedding-valeant-name-still-leans-price-hikes-analyst
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-xifaxan-21361-rifaximin-tablets-200-mg-1551935588.pdf
https://www.fiercepharma.com/marketing/cosmo-to-give-bausch-health-sales-a-run-latest-fda-nod-for-xifaxan-rival
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626121.htm?utm_campaign=FDA%20approves%20new%20treatment%20of%20travelers%E2%80%99%20diarrhea%20caused%20by%20noninvasive%20strains%20of%20Escherichia%20coli&utm_medium=email&utm_source=Eloqua
https://www.fiercepharma.com/marketing/bausch-health-aims-top-seller-xifaxan-at-new-diseases-to-max-out-growth
https://www.fiercepharma.com/marketing/valeant-partner-cosmo-turns-wannabe-ibs-d-rival-and-it-could-do-some-sales-damage-analyst
https://dcatvci.org/supplier-news/5002-friulchem-reports-on-patent-ruling-for-rifaximin
http://www.fiercepharma.com/marketing/copying-valeant-s-xifaxan-just-got-a-lot-easier-thanks-to-new-fda-guidance-analyst
http://www.fiercepharma.com/pharma/valeant-touts-salix-salesforce-scale-up-amid-rumors-mass-rep-exit
http://www.fiercepharma.com/marketing/how-much-can-a-new-evp-help-valeant-s-badly-battered-derm-unit
http://www.fiercepharma.com/marketing/valeant-looks-to-revive-xifaxan-primary-care-sales-effort-will-it-work
https://www.bloomberg.com/news/articles/2016-11-30/valeant-said-to-plan-to-keep-salix-after-takeda-deal-falls-apart
http://www.prnewswire.com/news-releases/valeant-announces-the-initiation-of-a-primary-care-sales-force-for-xifaxan-and-relistor-300369978.html
http://www.fiercepharma.com/marketing/allergan-teams-star-paratriathlete-yet-another-effort-to-boost-ibs-d-med-viberzi
http://www.fiercepharma.com/marketing/blam-takeda-s-superhero-adventures-are-back-four-new-characters-to-take-ibd
http://www.bloomberg.com/news/articles/2016-11-01/valeant-surges-on-report-it-s-in-talks-to-sell-salix-business
http://www.prnewswire.com/news-releases/la-rifaximin--para-la-encefalopatia-hepatica-puede-reducir-los-costes-a-los-sistemas-sanitarios-599394801.html
http://www.fiercepharma.com/marketing/allergan-teams-up-ibs-d-platform-to-identify-potential-new-viberzi-patients
http://www.fiercepharma.com/marketing/allergan-continues-viberzi-push-online-ibs-d-awareness-tool
http://www.reuters.com/article/us-valeant-investmentbanks-idUSKCN0XB2TJ
http://www.fiercepharmamarketing.com/story/vexing-ibs-d-spokescharacter-irritabelle-headlines-allergans-viberzi-ad-pus/2016-04-11
http://www.fiercepharmamarketing.com/story/abbvies-humira-pfizers-lyrica-kick-2016-hefty-tv-ad-spend/2016-03-09
http://www.fiercepharmamarketing.com/story/pharmas-dtc-ad-spending-soars-past-5-billion-2015/2016-03-07
http://www.fiercepharma.com/story/head-valeants-embattled-dermatology-unit-exits-management-shakeup/2016-03-03
http://twofourinsight.com/rhodes-pharma-aptensio-challenged-latest-usfda-para-4-certification-list/
http://www.prnewswire.com/news-releases/allergan-announces-receipt-of-fda-acceptable-for-filing-letter-for-generic-xifaxan-anda-300227436.html
http://www.fiercepharmamarketing.com/story/valeant-astrazeneca-played-super-bowl-ad-game-did-they-win/2016-02-08
http://www.fiercepharmamarketing.com/story/love-it-or-hate-it-valeants-wobbly-pink-gut-guy-xifaxan-getting-noticed/2015-12-10
http://www.fiercepharmamarketing.com/story/bms-opdivo-repeats-new-flu-ads-join-list-top-pharma-ad-spending-november/2015-12-14
http://www.prnewswire.com/news-releases/deux-nouvelles-analyses-prouvent-le-rapport-cout-efficacite-du-rifaximin--550mg-chez-des-patients-belges-et-neerlandais-atteints-dencephalopathie-hepatique-551894361.html
http://www.fiercepharmamarketing.com/story/abbvies-humira-repeats-joined-bms-opdivo-leading-tv-spending-october/2015-11-18
Market Place
Share 
